Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Virtual microscopy improves sharing of deceased donor kidneys.

Osband AJ, Fyfe B, Laskow DA.

Am J Surg. 2016 Oct;212(4):592-595. doi: 10.1016/j.amjsurg.2016.06.009.

PMID:
27530976
2.

Role of Coronary Angiography in the Assessment of Cardiovascular Risk in Kidney Transplant Candidates.

Mann DM, Fernandez S, Mondal Z, Laskow D, Osband A, Debroy M, Lebowitz J, Coromilas J, Vagaonescu T, Moreyra A, Melita EA, Mann RA.

Am J Cardiol. 2016 Sep 1;118(5):679-83. doi: 10.1016/j.amjcard.2016.06.017.

PMID:
27392506
3.

The Kidney Transplant Morbidity Index (KTMI): a simple prognostic tool to help determine outcome risk in kidney transplant candidates.

Pieloch D, Dombrovskiy V, Osband AJ, DebRoy M, Mann RA, Fernandez S, Mondal Z, Laskow DA.

Prog Transplant. 2015 Mar;25(1):70-6. doi: 10.7182/pit2015462.

PMID:
25758804
4.

Surgical resident perspective on deceased donor organ procurement.

Osband AJ, Laskow DA.

Am J Surg. 2015 Jun;209(6):1090-4. doi: 10.1016/j.amjsurg.2014.08.039.

PMID:
25601558
5.

The impact of morbid obesity on hospital length of stay in kidney transplant recipients.

Pieloch D, Mann R, Dombrovskiy V, DebRoy M, Osband AJ, Mondal Z, Fernandez S, Laskow DA.

J Ren Nutr. 2014 Nov;24(6):411-6. doi: 10.1053/j.jrn.2014.05.007.

PMID:
25091137
6.

Morbid obesity is not an independent predictor of graft failure or patient mortality after kidney transplantation.

Pieloch D, Dombrovskiy V, Osband AJ, Lebowitz J, Laskow DA.

J Ren Nutr. 2014 Jan;24(1):50-7. doi: 10.1053/j.jrn.2013.07.001.

PMID:
24070588
7.

Sarcoidosis within a renal allograft: a case report and review of the literature.

Mann DM, Fyfe B, Osband AJ, Lebowitz J, Laskow DA, Jones J, Mann RA.

Transplant Proc. 2013 Mar;45(2):838-41. doi: 10.1016/j.transproceed.2012.11.008. Review.

PMID:
23498832
8.

Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal.

Gaber AO, Moore LW, Alloway RR, Woodle ES, Pirsch J, Shihab F, Henning A, Fitzsimmons W, Holman J, Reisfield R, First MR; Astellas Corticosteroid Withdrawal Study Group..

Transplantation. 2013 Feb 27;95(4):573-9. doi: 10.1097/TP.0b013e3182777efb.

PMID:
23423269
9.

Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study.

Shihab FS, Lee ST, Smith LD, Woodle ES, Pirsch JD, Gaber AO, Henning AK, Reisfield R, Fitzsimmons W, Holman J; M. R. First for the Astellas Corticosteroid Withdrawal Group..

Am J Transplant. 2013 Feb;13(2):474-84. doi: 10.1111/j.1600-6143.2012.04327.x.

10.

Spermatocele following kidney transplant.

Osband AJ, Laskow DA.

Am J Transplant. 2012 Jul;12(7):1936-7. doi: 10.1111/j.1600-6143.2012.04043.x.

11.

Treatment of acute graft-vs-host disease after simultaneous pancreas-kidney transplantation: a case report.

Osband AJ, Laskow DA, Mann RA.

Transplant Proc. 2010 Nov;42(9):3894-7. doi: 10.1016/j.transproceed.2010.08.058.

PMID:
21094880
12.

Quiz page July 2009. Fever and neutropenia following simultaneous pancreas-kidney transplantation. Graft-versus-host disease.

Osband AJ, Laskow DA, Berkowicz T, Mann RA.

Am J Kidney Dis. 2009 Jul;54(1):A35-7. doi: 10.1053/j.ajkd.2009.03.014. No abstract available.

PMID:
19559333
13.

Sweet syndrome after kidney transplantation.

Osband AJ, Laskow DA, Mann RA, Berkowicz T, Ianosi-Irimie M, Boruchoff S.

Transplant Proc. 2009 Jun;41(5):1954-6. doi: 10.1016/j.transproceed.2009.03.067.

PMID:
19545765
14.

A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.

Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P; Astellas Corticosteroid Withdrawal Study Group..

Ann Surg. 2008 Oct;248(4):564-77. doi: 10.1097/SLA.0b013e318187d1da.

PMID:
18936569
15.

Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.

Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M; CRADUS09 Study Group..

Transplantation. 2008 Mar 27;85(6):821-6. doi: 10.1097/TP.0b013e318166927b.

PMID:
18360262
16.

A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.

Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M.

Am J Transplant. 2007 Jul;7(7):1770-7.

17.

Sirolimus lowers myeloperoxidase and p-ANCA titers in a pediatric patient before kidney transplantation.

Constantinescu AR, Liang M, Laskow DA.

Am J Kidney Dis. 2002 Aug;40(2):407-10.

PMID:
12148116
18.

Dialysis access failure: an indication for immediate kidney transplantation.

Laskow DA, Ahsan N.

Semin Dial. 2002 Jan-Feb;15(1):1-2.

PMID:
11874580
19.

Transforming growth factor-beta levels in human allograft chronic fibrosis correlate with rate of decline in renal function.

Cuhaci B, Kumar MS, Bloom RD, Pratt B, Haussman G, Laskow DA, Alidoost M, Grotkowski C, Cahill K, Butani L, Sturgill BC, Pankewycz OG.

Transplantation. 1999 Sep 27;68(6):785-90.

PMID:
10515378
20.

The role of tacrolimus in adult kidney transplantation: a review.

Laskow DA, Neylan JF 3rd, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ.

Clin Transplant. 1998 Dec;12(6):489-503. Review.

PMID:
9850440

Supplemental Content

Loading ...
Support Center